Search research articles
Contact Us
Filters
Showing results (11-20 of 79) with videos related to
Page
of 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 3, 2009
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A
J Klintman, E Berntorp, J Astermark, et al.
Haematologica
|
February 24, 2001
Immune tolerance induction and the treatment of hemophilia. Malmö protocol update
E Berntorp, J Astermark, E Carlborg
British Journal of Haematology
|
December 31, 1997
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
J Astermark, M Ekman, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 2, 2010
Clinical issues in inhibitors
J Astermark, E Santagostino, W Keith Hoots
The Journal of Biological Chemistry
|
February 4, 1994
The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation
J Astermark, P J Hogg, J Stenflo
Journal of Thrombosis and Haemostasis : JTH
|
August 1, 2012
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
C Hermans, J Astermark, P De Moerloose
Thrombosis Research
|
April 27, 2001
Anti- and procoagulant activities in factor VII-deficient subjects
J Astermark, L Tengborn, U Hedner, et al.
Lakartidningen
|
February 12, 1998
[Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates]
J Astermark, E Berntorp, L Stigendal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 25, 2008
Inhibitor development
J Astermark, S Lacroix-Desmazes, M T Reding
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 2, 2010
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis
M Khawaji, J Astermark, K Akesson, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 79) with videos related to
Sort By:
Page
of 8
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 3, 2009
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A
J Klintman, E Berntorp, J Astermark, et al.
Haematologica
|
February 24, 2001
Immune tolerance induction and the treatment of hemophilia. Malmö protocol update
E Berntorp, J Astermark, E Carlborg
British Journal of Haematology
|
December 31, 1997
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
J Astermark, M Ekman, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 2, 2010
Clinical issues in inhibitors
J Astermark, E Santagostino, W Keith Hoots
The Journal of Biological Chemistry
|
February 4, 1994
The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation
J Astermark, P J Hogg, J Stenflo
Journal of Thrombosis and Haemostasis : JTH
|
August 1, 2012
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
C Hermans, J Astermark, P De Moerloose
Thrombosis Research
|
April 27, 2001
Anti- and procoagulant activities in factor VII-deficient subjects
J Astermark, L Tengborn, U Hedner, et al.
Lakartidningen
|
February 12, 1998
[Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates]
J Astermark, E Berntorp, L Stigendal, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 25, 2008
Inhibitor development
J Astermark, S Lacroix-Desmazes, M T Reding
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 2, 2010
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis
M Khawaji, J Astermark, K Akesson, et al.
Page
of 8